IJNRD.ORG ISSN : 2456-4184

INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG

An International Open Access, Peer-reviewed, Refereed Journal

Toxicokinetic evaluation in preclinical studies and applications of toxicokinetic

Ms. Jadhav Supriya Kailas, Mr. Kale Atulkumar Bajirao, Miss. Pooja Sudam Waje, Ms.Deore Sonika Balchand, Mr. Aniket Dhulap

Lecturer, Student, Student, Lecturer, Student

Matoshri college of pharmacy, Eklahare,Nashik, Aditya Pharmacy College Beed, PRES's COP chincholi nasik **, Matoshri college of pharmacy, Eklahare,Nashik, National Institute of Pharmaceutical Education and Research NIPER Hajipur**

ABSTRACT

Toxicokinetic assessment is both a monitoring tool and a scientific necessity in the drug development process. Toxicokinetic involves the generation of dynamic data to evaluate systemic exposure, either as an integral part of preclinical toxicity studies or in specifically designed supportive studies. This information helps in understanding the relationship between observed toxicity and the administered dose. Additionally, toxicokinetic assessment plays a crucial role in the clinical setting, aiding in the determination of plasma thresholds for early human exposure and in the estimation of safety margins.

- **Definition of Toxicokinetics (TK):** Introduce toxicokinetics as the study of how a substance enters, distributes, metabolizes, and exits an organism.
- **Importance in Preclinical Studies:** Discuss the role of TK in predicting the safety profile of new drugs or chemicals before they are tested in humans.

❖ INTRODUCTION

Toxicokinetics (TK) is a critical field within pharmacology and toxicology that focuses on the study of how a chemical substance or drug is absorbed, distributed, metabolized, and excreted (ADME) in an organism, particularly at doses that may cause toxicity. Unlike traditional pharmacokinetics, which primarily deals with therapeutic doses, toxicokinetics often involves the study of higher, potentially harmful doses to understand the drug's behavior under conditions that may lead to adverse effects.

The primary objective of toxicokinetic studies is to correlate systemic exposure with toxicological outcomes, providing valuable insights into the dose-response relationship. By characterizing the time course of a substance in the body, toxicokinetics helps in identifying potential risks and guiding safe dosing regimens.

In the context of drug development, toxicokinetic evaluations are essential for predicting the safety profile of new therapeutic agents. They serve as a bridge between preclinical studies and clinical trials, helping to establish safe starting doses for first-in-human studies and to define exposure limits. Moreover, toxicokinetic data support the interpretation of toxicity findings from animal studies and play a pivotal role in the risk assessment process, ultimately contributing to the protection of human health.

Moreover, toxicokinetics plays a critical role in bridging preclinical findings with human studies. The data generated from toxicokinetic evaluations are used to set safe starting doses for first-in-human trials, to anticipate possible adverse effects, and to determine safety margins. These studies are also pivotal in regulatory submissions, providing evidence that supports the safety of a drug for human use. Toxicokinetics is not only concerned with the characterization of systemic exposure but also with understanding the factors that influence it, such as species differences, age, sex, genetic polymorphisms, and the impact of disease states. These factors can significantly alter the toxicokinetic profile of a substance, affecting its safety and efficacy.

In conclusion, toxicokinetics is an essential component of the drug development process, ensuring that new drugs are not only effective but also safe for human use. By providing a comprehensive understanding of how drugs and chemicals interact with biological systems at potentially toxic levels, toxicokinetic studies help to safeguard public health and to prevent adverse drug reactions in clinical practice.

❖ DEFINITION

Toxicokinetics deals with the study of the absorption, biotransformation, distribution, and excretion of chemical substances. It explains the rate at which a chemical enters the body, how it is metabolized, and how the compound is ultimately excreted once it is inside the body.



Toxicokinetic Parameters

Toxicokinetic parameters are quantitative measures that describe the behavior of a chemical or drug within an organism, particularly at doses that may lead to toxicity. These parameters are crucial for understanding the absorption, distribution, metabolism, and excretion (ADME) processes of a substance, and they help establish the relationship between exposure and toxicological effects. Key toxicokinetic parameters include:

1. Cmax (Maximum Concentration): The highest concentration of the substance in the blood or plasma after administration. It indicates the peak exposure of the organism to the substance.

2. Tmax (Time to Maximum Concentration): The time it takes to reach the maximum concentration (Cmax) after administration. This parameter provides insight into the absorption rate of the substance.

3. AUC (Area Under the Curve): Represents the total exposure of the organism to the substance over time. The AUC is a crucial parameter as it correlates with the extent of systemic exposure and potential toxicity.

4. Half-Life (t1/2): The time required for the concentration of the substance in the blood or plasma to decrease by half. The half-life gives an indication of how long the substance stays in the body and is important for understanding the duration of exposure.

5. Volume of Distribution (Vd): A theoretical volume that represents the distribution of the substance throughout the body's tissues. A high Vd indicates extensive distribution into tissues, while a low Vd suggests that the substance remains mostly in the bloodstream.

6. Clearance (Cl): The rate at which the substance is removed from the body, usually through metabolism and excretion. Clearance is a critical parameter for determining how long a substance will remain in the system and its potential to accumulate with repeated dosing.

7. Bioavailability (F): The fraction of the administered dose that reaches the systemic circulation in an active form. Bioavailability is important for understanding the efficiency of absorption and the overall exposure of the organism to the substance.

8. Steady-State Concentration (Css): The concentration at which the rate of administration equals the rate of elimination, resulting in a stable concentration of the substance in the bloodstream during continuous dosing.

9. Absorption Rate Constant (Ka): The rate at which the substance is absorbed into the systemic circulation from the site of administration. A higher Ka indicates faster absorption.

10. Lag Time (Tlag): The delay between the administration of the substance and the beginning of its absorption into the bloodstream.

11. Metabolic Rate Constant (Km): Describes the rate of metabolism of the substance. It is particularly important in toxicokinetics when dealing with substances that are metabolized to toxic metabolites.

❖ **PRINCIPLE**

1. Absorption

- **Definition:** Absorption refers to the process by which a substance enters the bloodstream from the site of administration (e.g., oral, intravenous, dermal).
- **Principles:**

Bioavailability: Determines the fraction of the administered dose that reaches the systemic circulation in an active form.

Rate of Absorption: Influenced by factors such as the substance's solubility, the formulation, and the site of administration.

First-Pass Metabolism: For orally administered substances, the first-pass effect in the liver can significantly reduce the amount of the substance that enters systemic circulation.

2. Distribution

- **Definition:** Distribution is the process by which a substance spreads throughout the body's tissues and organs after entering the bloodstream.
- **Principles:**

Volume of Distribution (Vd): A key parameter that reflects the extent to which a substance is distributed in body tissues versus remaining in the blood.

Plasma Protein Binding: The extent to which a substance binds to proteins in the blood can affect its distribution and availability to tissues.

Tissue Affinity: Some substances may preferentially accumulate in specific tissues, which can lead to localized toxicity.

3. Metabolism (Biotransformation)

- **Definition:** Metabolism involves the chemical modification of a substance by the body, usually in the liver, to make it easier to excrete.
- **Principles:**

Phase I and Phase II Reactions: Metabolism typically occurs in two phases—Phase I (modification, such as oxidation) and Phase II (conjugation, making the substance more water-soluble).

Enzyme Saturation: At toxic doses, metabolic enzymes can become saturated, leading to non-linear kinetics and increased toxicity.

Formation of Toxic Metabolites: Some substances are metabolized into reactive or toxic intermediates that can cause cellular damage.

4. Excretion

- **Definition:** Excretion is the process by which the body removes the substance, primarily through the kidneys (urine) or the liver (bile and feces).
- **Principles:**

Clearance (Cl): The rate at which a substance is removed from the body, an essential parameter for understanding how long the substance remains in the system.

Renal and Hepatic Excretion: The efficiency of excretion via the kidneys or liver can significantly influence the toxicokinetic profile, especially in cases of impaired organ function.

Biliary Excretion and Enterohepatic Recycling: Some substances are excreted into the bile, reabsorbed from the intestine, and re-enter the systemic circulation, prolonging their presence in the body.

5. Dose-Response Relationship

- **Definition:** The dose-response relationship describes how the body's response to a substance changes with the level of exposure.
- **Principles:**

Threshold Dose: The minimum dose required to produce a measurable effect, below which no significant toxic response is observed.

Non-Linear Kinetics: At higher doses, the relationship between dose and systemic exposure can become non-linear due to saturation of absorption, metabolism, or excretion processes.

Toxicokinetic/Pharmacokinetic (TK/PK) Relationship: The correlation between the toxicokinetic profile and the observed toxic effects, which helps in risk assessment and dose adjustment.

6. Inter-Species Extrapolation

- **Definition:** The process of translating toxicokinetic data from animal studies to predict human responses.
- **Principles:**

Allometric Scaling: Adjusting toxicokinetic parameters based on body size and metabolic rate differences between species.

Species-Specific Metabolism: Recognizing differences in metabolic pathways between species that can impact the toxicity and behavior of substances.

7. Saturation Kinetics

- **Definition:** Saturation kinetics occurs when the processes of absorption, metabolism, or excretion become saturated at higher concentrations, leading to non-linear increases in systemic exposure.
- **Principles:**

Non-Linear Dose Response: At toxic doses, a small increase in dose may lead to a disproportionately large increase in systemic concentration.

Enzyme Capacity: Once the metabolic or transport systems are saturated, the elimination of the substance slows down, potentially increasing toxicity.

- **Toxicokinetics and Pathology: Interpretation of Data in an Integrated Fashion**

1. Correlation Between Exposure and Toxicity

Systemic Exposure: Toxicokinetic studies provide detailed information about the concentration of a substance in the blood and tissues over time. By understanding how much of a substance is absorbed, how it is distributed, and how long it stays in the body, toxicologists can correlate these parameters with observed toxic effects.

Pathological Findings: Pathology, which includes the study of structural and functional changes in tissues caused by the substance, provides direct evidence of toxicity. By correlating TK data with pathology results, researchers can identify whether the toxic effects seen in tissues correspond with high levels of the substance in those tissues.

2. Dose-Response Relationships

TK and Dose-Response: Toxicokinetics helps establish the dose-response relationship by linking the administered dose of a substance to the systemic exposure (e.g., peak concentration, area under the curve). Understanding this relationship is crucial for predicting the likelihood and severity of toxic effects at different dose levels. Pathological Confirmation: Pathological data confirm the toxic effects suggested by the dose-response relationship. For instance, if TK data show high exposure at a certain dose, pathology can reveal specific tissue damage that aligns with this exposure.

3. Mechanisms of Toxicity Metabolite Formation: Toxicokinetic studies often reveal the formation of metabolites, some of which may be more toxic than the parent compound. By identifying these metabolites and correlating their presence with pathological changes, researchers can uncover the mechanisms behind the observed toxicity. Pathological Insights: Pathological examination can provide clues about the mechanism of toxicity, such as oxidative stress, inflammation, or apoptosis, which can be linked back to the toxicokinetic profile, including the timing and concentration of toxic metabolites.

4. Time Course of Toxicity Temporal TK Data: Toxicokinetics provides a time course of substance concentration in the body, which is crucial for understanding when and for how long tissues are exposed to potentially toxic levels. Pathology Over Time: By conducting pathology at different time points, researchers can observe how tissue damage progresses and recovers, if applicable. This temporal alignment of TK data with pathological findings helps in determining the critical windows of exposure that lead to toxicity.

5. Saturation Kinetics and Non-Linear Toxicity TK Indications of Saturation: Toxicokinetic data can indicate when metabolic or excretory pathways become saturated, leading to non-linear increases in systemic exposure. Such conditions often result in disproportionate toxic effects at higher doses. Pathological Correlation: Pathology can reveal the consequences of saturation kinetics, such as unexpected severe tissue damage at doses that initially seemed safe. This helps in understanding the limits of safe exposure and the risks of escalating doses.

6. Species Differences and Extrapolation TK Data Across Species: Toxicokinetics allows comparison of systemic exposure across different animal models, which is essential for extrapolating data to humans. This involves accounting for species-specific differences in metabolism, distribution, and excretion. Pathological Comparisons: Pathological findings can vary significantly between species. By integrating TK data with pathology, researchers can better understand these differences and improve the accuracy of human risk assessments.

7. Integration in Risk Assessment and Drug Development Regulatory Decisions: The integration of toxicokinetic and pathological data is fundamental in risk assessment, guiding the establishment of safe exposure limits and identifying potential risks for humans. Regulatory agencies often require this integrated data to make informed decisions about the safety of new drugs or chemicals.Drug Development: In drug development, combining TK data with pathology helps identify potential toxic effects early in the process, allowing for modifications in drug design or dosing strategies to mitigate risks before clinical trials.

Applications of Toxicokinetics

1. Drug Development Dose Selection for Preclinical Studies: Toxicokinetic studies are essential in determining appropriate dose levels for preclinical toxicity studies. By understanding the systemic exposure of a drug, researchers can select doses that are likely to produce a measurable toxic effect without being excessively harmful.

First-in-Human Dose Prediction: TK data from animal studies help in predicting safe starting doses for first-in-human (FIH) clinical trials. This is crucial in minimizing the risk of adverse effects during the initial phases of drug testing in humans.

Optimizing Dosing Regimens: TK studies guide the design of dosing regimens by providing information on the absorption, distribution, metabolism, and excretion of a drug. This helps in optimizing dose intervals and adjusting doses to achieve the desired therapeutic effect while minimizing toxicity.

2. Safety Assessment and Risk Management

Establishing Safety Margins: Toxicokinetics helps in establishing the safety margin of a drug or chemical by comparing the exposure levels at which adverse effects occur to those expected in humans at therapeutic or environmental exposure levels.

Identification of Toxic Metabolites: Through toxicokinetic studies, researchers can identify and quantify toxic metabolites, which may contribute to adverse effects. Understanding the formation and elimination of these metabolites is crucial for assessing the overall safety of a substance.

Non-Clinical Risk Assessment: TK data are used to predict potential human risks based on animal studies. By comparing toxicokinetic profiles across species, researchers can better assess the relevance of animal toxicity findings to humans.

3. Regulatory Toxicology

Supporting Regulatory Submissions: Toxicokinetic data are often required in regulatory submissions for new drugs, chemicals, and environmental contaminants. Agencies such as the FDA, EMA, and EPA use TK data to assess the safety and efficacy of substances before approving them for use.

Setting Exposure Limits: Regulatory bodies rely on toxicokinetic data to establish occupational, environmental, and dietary exposure limits. These limits are based on understanding the relationship between exposure levels and the risk of adverse effects.

Evaluating Drug-Drug Interactions: TK studies are used to evaluate potential drug-drug interactions by assessing how co-administration of different drugs affects their absorption, metabolism, and excretion, which can lead to altered efficacy or increased toxicity.

4. Environmental Toxicology

Assessing Environmental Contaminants: Toxicokinetic principles are applied to study the behavior of environmental contaminants in organisms, including their bioaccumulation, persistence, and potential for causing harm to wildlife and humans.

Biomonitoring: TK data are used in biomonitoring studies to evaluate the internal exposure of organisms, including humans, to environmental chemicals. This helps in assessing the risk of chronic exposure to low levels of contaminants.

5. Clinical Toxicology

Overdose Management: In cases of drug overdose, TK data help clinicians understand the expected time course of drug concentrations in the body, guiding the use of antidotes and supportive care.

Therapeutic Drug Monitoring (TDM): Toxicokinetics is used in TDM to optimize drug dosing in individual patients, ensuring therapeutic efficacy while avoiding toxic side effects, especially for drugs with narrow therapeutic windows.



Poisoning and Toxic Exposure: TK data are crucial in understanding how quickly a toxicant is absorbed and eliminated, which informs treatment decisions in cases of poisoning or exposure to hazardous substances.

6. Veterinary Toxicology

Animal Health and Safety: TK studies are used in veterinary medicine to assess the safety of drugs and chemicals in animals, ensuring that treatments are effective and safe for both domestic animals and livestock.

Residue Analysis: Toxicokinetics helps in determining the withdrawal periods for drugs used in food-producing animals, ensuring that any residues in meat, milk, or eggs are below regulatory limits and safe for human consumption.

7. Forensic Toxicology

Interpretation of Toxicological Findings: In forensic investigations, TK data assist in interpreting post-mortem toxicology results, helping to determine the time and dose of substance ingestion, and contributing to the understanding of cause of death or impairment.

Legal and Criminal Investigations: TK studies provide evidence in legal cases involving drug use, poisoning, or environmental exposure, helping to establish timelines and the potential impact of toxic substances.

❖ CONCLUSION

Integrating toxicokinetics with pathology provides a holistic understanding of the toxicological profile of a substance. While toxicokinetics offers insights into systemic exposure and the dynamics of a substance within the body, pathology provides concrete evidence of the effects of this exposure on tissues and organs. Together, they allow for a more accurate interpretation of data, leading to better risk assessments, safer drug development, and more informed regulatory decisions. This integrated approach is essential for identifying toxic risks, understanding mechanisms of toxicity, and ultimately ensuring the safety of chemical substances and pharmaceuticals. The applications of toxicokinetics are diverse and integral to many aspects of public health, drug development, and environmental protection. By providing detailed insights into how substances interact with biological systems at potentially toxic levels, toxicokinetics helps in ensuring the safety and efficacy of drugs, chemicals, and environmental agents. Its role in regulatory science, clinical practice, and forensic investigations underscores its importance in safeguarding human and animal health.

❖ REFERENCE

1) Clark B and Smith DA (1984). Pharmacokinetics and toxicity testing. CRCCrit. Rev. Tasicol. Pageno- 343-385.

2) OECD Test guideline 426: developmental neurotoxicity study. OECD guidelines for the testing of chemicals, 2007.

3) Pharmacology, Part 2: Introduction to Pharmacokinetics JNMT https://tech.snmjournals.org/

4) Toxicokinetic Evaluation In Preclinical Studies WORLD JOURNAL OF PHARMACY AND PHARMACEUTICALSCIENCES File:///C:/Users/PC34/Appdata/Local/Temp/2/Rar$Dia0.053/TOXICOKINETIC%20EVALUATION%20IN%20PRECLINICAL%20STUDIES.Pdf

5) Toxicokinetic springer link https://link.springer.com/chapter/10.1007/978-3-642-78680-8_14

6) OECD draft guidance document on the design and conduct of chronic toxicity and carcinogenicity studies, supporting TG 451, 452 and 453. Draft ENV/JM/TG(2009).

7) Brodie BB and Reid WD. The value of deter- mining the plasma concentration of drugs in animals and man. In: Firndanienfals of Drug hfetabolism and Qisposirion, BN LaDu, HG Mandel, and EL Way (eds). Williams and Wilkins, Baltimore, Maryland, 1971.

8) WHO. (2020). *Environmental Health Criteria 240: Principles for Evaluating Health Risks in Children Associated with Exposure to Chemicals*. World Health Organization.

9) Gibaldi, M., & Perrier, D. (1982). *Pharmacokinetics*. Marcel Dekker.

10) Sipes, I. G., & Gandolfi, A. J. (Eds.). (2011). *Introduction to Toxicology* (3rd ed.). CRC Press.